Tag: Biotech and Pharma

Merck KGaA (MRCG.DE),  has struck a deal to buy U.S. biotech company SpringWorks Therapeutics (SWTX.O),  for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.

AbbVie (ABBV +3.15%) gave investors reason to cheer, reporting higher earnings than expected for a fifth straight quarter and raising its financial forecasts for the year.

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its latest financial results late Thursday should reinforce its position

Οι επενδύσεις μας αποδίδουν και ενισχύουν σημαντικά την κερδοφορία μας. Μετά από 18 χρόνια ανταμείβουμε τους μετόχους για την εμπιστοσύνη τους, διανέμοντας μέρισμα (2 λεπτά/ανά μετοχή)», δήλωσε ο CFO του ομίλου.

Bristol Myers Squibb reported better-than-expected earnings for the first quarter and boosted its outlook while noting the impact of stiff competition in the pharmaceutical market.

Bristol Myers Squibb’s Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with schizophrenia.

Swiss pharmaceutical giant Roche on Tuesday said that it would invest $50 billion in the U.S. over the next five years, amid concerns about the impact of possible new White House tariffs on pharma goods from abroad.

Eli Lilly (LLY.N),  said on Thursday its experimental pill, orforglipron, led to weight loss of nearly 8% at the highest dose and lowered blood sugar in patients with type 2 diabetes in a late-stage trial.

Abbott Laboratories ABT-0.90% declined slightly in premarket trading Wednesday after the healthcare company posted first-quarter sales that missed Wall Street expectations.

J&J beat quarterly profit and revenue expectations and raised its dividend but didn’t change its profit outlook, and the stock pulled back.

Οι εφαρμογές θα εστιάζουν στη διαχείριση του πόνου με βάση τις εγκεκριμένες ενδείξεις των αντίστοιχων φαρμάκων, συμπεριλαμβανομένων των τελικών προϊόντων φαρμακευτικής κάνναβης . 

Pfizer stock fell after suffering a setback developing a new weight-loss drug.

A U.S. bankruptcy judge on Monday rejected Johnson & Johnson’s (JNJ.N), opens new tab $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company’s bankruptcy strategy has failed in court.

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with diabetes and heart disease. 

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player.

Bayer shares fell sharply after the company was ordered to pay $2.1 billion by a jury in a Georgia state court, the latest legal defeat for the company in a case about its Roundup weedkiller.

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.

Johnson & Johnson  plans to spend over $55 billion to build four plants in the U.S., it said on Friday, as a threat of drug import duties from the Trump administration forces companies to expand their manufacturing operations domestically.

Σε 61,01 εκατ. ευρώ ανήλθαν οι ενοποιημένες Πωλήσεις από συνεχιζόμενη δραστηριότητα, προ Rebate & Clawback της Lavipharm παρουσιάζοντας αύξηση κατά 12,3%.